NCT07369830 The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function
| NCT ID | NCT07369830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | Rectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 156 participants in total. It began in 2025-10-15 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to propose a novel, easy-to-operate intervention strategy that effectively improves defecation function after stoma reversal and to assess its impact on the gut microbiota.The efficacy and safety of antegrade placement of probiotics into the distal deserted intestine during prophylactic stoma to improve bowel function after stoma reversal were evaluated through randomized controlled clinical trials.Observing the changes in gut microbiota during the prophylactic stoma period, the impact of probiotics on the structure of gut microbiota, and exploring the correlation between gut genera and bowel function after stoma reversal.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 75 years 2. Ultra low rectal cancer meeting the indication for Intersphincteric Resection (ISR) surgery 3. Underwent a prophylactic ileostomy 4. Scheduled for stoma reversal surgery within 6 months after the ISR procedure 5. Digestive tract reconstruction achieved via either hand-sewn or stapled coloanal anastomosis 6. Patient has a strong preference for undergoing sphincter-preserving surgery 7. Capable of understanding and willing to provide signed informed consent Exclusion Criteria: 1. Does not meet the surgical indications for Intersphincteric Resection (ISR) 2. Presence of multiple primary colorectal malignancies 3. Patients who have received neoadjuvant radiotherapy 4. Patients who experience disease progression or death in the postoperative period 5. Patients who develop severe anastomotic complications postoperatively, such as anastomotic leakage or stenosis 6. Patients whose actual stoma reversal surgery occurs more than 6 months after the ISR procedure 7. Patients who require long-term(more than 3 months) use of antibiotics 8. History of allergy to Clostridium butyricum (live) Tablets (MIYA) or any of its components 9. Concurrent use of other probiotic during the study period 10. Coexisting inflammatory bowel disease 11. History of neurological or psychiatric disorders, including but not limited to Parkinson's disease, Alzheimer's disease, organic brain diseases, stroke, epilepsy, or major psychiatric disorders (e.g., major depressive disorder) 12. Pregnant or lactating women
Contact & Investigator
Xiang Jianbin, Doctor
PRINCIPAL INVESTIGATOR
Huashan Hospital
Frequently Asked Questions
Who can join the NCT07369830 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07369830 currently recruiting?
Yes, NCT07369830 is actively recruiting participants. Contact the research team at 13764030915@163.com for enrollment information.
Where is the NCT07369830 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07369830 clinical trial?
NCT07369830 is sponsored by Huashan Hospital. The principal investigator is Xiang Jianbin, Doctor at Huashan Hospital. The trial plans to enroll 156 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.